This is worth flagging because many clients establish a timing habit during escalation choosing morning or evening based on side effect management and then never revisit the decision once the protocol has stabilized
T32HL076139 to C.R.R
& Jakobkiewicz-Banecka, J
it is recruiting 1,800 participants with type 2 diabetes Clinical Trials Identifier: NCT030495102 Trial name: A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants with Type 2 Diabetes (AWARD-11) Diabetes type: Type 2 What the trial is testing: This study will test the effectiveness of different doses of Trulicity (dulaglutide), a GLP-1 agonist, in addition to metformin for type 2 diabetes
Cody Coonradt, Market Development and Strategy Manager 3M Health Information Systems, Leader in Health care Coding, Payment & Analytics Solutions
Your physician or Nurse Practitioner prescribes your GLP-1 medication, personalizes your dose, and monitors your progress at every visit